Eiko Lifesciences Ltd
₹ 51.6
-0.39%
12 Jun
- close price
About
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
Key Points
- Market Cap ₹ 74.0 Cr.
- Current Price ₹ 51.6
- High / Low ₹ 65.9 / 45.9
- Stock P/E 20.7
- Book Value ₹ 47.0
- Dividend Yield 0.00 %
- ROCE 7.65 %
- ROE 5.78 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.10 times its book value
- Company is expected to give good quarter
- Promoter holding has increased by 2.74% over last quarter.
- Company's working capital requirements have reduced from 155 days to 89.8 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 39.9%
- Company has a low return on equity of 3.73% over last 3 years.
- Earnings include an other income of Rs.2.13 Cr.
- Company has high debtors of 164 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.58 | 0.40 | 0.51 | 0.39 | 0.00 | 11.99 | 25.41 | 18.32 | 27.93 | 32.49 | 42.13 | |
| 0.08 | 0.47 | 0.14 | 0.18 | 0.20 | 0.17 | 11.47 | 24.10 | 17.35 | 26.31 | 30.78 | 38.80 | |
| Operating Profit | 0.03 | 0.11 | 0.26 | 0.33 | 0.19 | -0.17 | 0.52 | 1.31 | 0.97 | 1.62 | 1.71 | 3.33 |
| OPM % | 27.27% | 18.97% | 65.00% | 64.71% | 48.72% | 4.34% | 5.16% | 5.29% | 5.80% | 5.26% | 7.90% | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.46 | 0.67 | 0.85 | 0.18 | 1.37 | 2.13 | |
| Interest | 0.00 | 0.00 | 0.02 | 0.05 | 0.03 | 0.07 | 0.09 | 0.48 | 0.16 | 0.15 | 0.13 | 0.16 |
| Depreciation | 0.00 | 0.00 | 0.02 | 0.06 | 0.06 | 0.06 | 0.06 | 0.56 | 0.63 | 0.66 | 0.63 | 0.59 |
| Profit before tax | 0.03 | 0.11 | 0.22 | 0.22 | 0.10 | 0.13 | 0.83 | 0.94 | 1.03 | 0.99 | 2.32 | 4.71 |
| Tax % | 33.33% | 27.27% | 27.27% | 13.64% | 30.00% | 0.00% | 26.51% | 24.47% | 25.24% | 23.23% | 24.57% | 23.99% |
| 0.02 | 0.08 | 0.17 | 0.18 | 0.07 | 0.13 | 0.61 | 0.71 | 0.77 | 0.75 | 1.74 | 3.58 | |
| EPS in Rs | 0.04 | 0.16 | 0.34 | 0.28 | 0.11 | 0.20 | 0.95 | 0.51 | 0.55 | 0.64 | 1.40 | 2.50 |
| Dividend Payout % | 0.00% | 0.00% | 44.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 54% |
| 5 Years: | 29% |
| 3 Years: | 32% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 46% |
| 5 Years: | 42% |
| 3 Years: | 68% |
| TTM: | 144% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -5% |
| 1 Year: | 2% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.02 | 3.02 | 3.02 | 3.82 | 3.82 | 3.82 | 3.82 | 8.32 | 8.32 | 12.87 | 13.76 | 14.35 |
| Reserves | 0.02 | 0.10 | 0.21 | 1.73 | 1.61 | 1.66 | 8.71 | 20.31 | 21.11 | 37.81 | 42.66 | 53.15 |
| 0.00 | 0.25 | 0.41 | 0.37 | 0.31 | 0.26 | 1.83 | 4.63 | 0.05 | 0.00 | 1.75 | 1.67 | |
| 0.01 | 0.02 | 0.12 | 0.06 | 0.02 | 0.02 | 2.25 | 1.64 | 1.57 | 2.06 | 2.21 | 13.62 | |
| Total Liabilities | 3.05 | 3.39 | 3.76 | 5.98 | 5.76 | 5.76 | 16.61 | 34.90 | 31.05 | 52.74 | 60.38 | 82.79 |
| 0.00 | 0.00 | 0.49 | 0.43 | 0.37 | 0.31 | 0.25 | 14.29 | 13.88 | 13.57 | 14.26 | 13.67 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.26 | 2.59 | 2.45 | 3.58 | 2.13 | 0.50 | 0.22 | 0.20 | 0.05 | 4.02 | 7.07 | 15.15 |
| 2.79 | 0.80 | 0.82 | 1.97 | 3.26 | 4.95 | 16.14 | 20.41 | 17.12 | 35.15 | 39.05 | 53.97 | |
| Total Assets | 3.05 | 3.39 | 3.76 | 5.98 | 5.76 | 5.76 | 16.61 | 34.90 | 31.05 | 52.74 | 60.38 | 82.79 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | 0.19 | 0.19 | 0.24 | -0.19 | 0.77 | -0.83 | -7.73 | 4.22 | -7.08 | 2.05 | ||
| -2.75 | 0.05 | -0.38 | -1.33 | -0.43 | -0.65 | -2.94 | 0.59 | 0.87 | -0.55 | -9.85 | ||
| 2.80 | 0.25 | 0.15 | 1.82 | -0.08 | -0.13 | 7.81 | 3.28 | -4.70 | 20.36 | 5.97 | ||
| Net Cash Flow | 0.01 | 0.49 | -0.04 | 0.72 | -0.71 | -0.01 | 4.05 | -3.85 | 0.40 | 12.73 | -1.83 | |
| Free Cash Flow | -0.05 | 0.19 | -0.33 | 0.24 | -0.19 | 0.77 | -0.83 | -7.88 | 4.00 | -7.43 | 0.72 | |
| CFO/OP | -133% | 191% | 96% | 85% | -84% | -459% | -125% | -574% | 427% | -435% | 137% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 331.82 | 0.00 | 0.00 | 0.00 | 74.87 | 103.81 | 65.50 | 141.66 | 171.59 | 113.92 | 163.66 | |
| Inventory Days | 2.06 | 88.26 | 20.64 | 48.70 | 50.23 | 38.86 | ||||||
| Days Payable | 65.30 | 21.82 | 23.82 | 19.82 | 13.87 | 121.67 | ||||||
| Cash Conversion Cycle | 331.82 | 0.00 | 0.00 | 0.00 | 74.87 | 40.57 | 131.94 | 138.48 | 200.46 | 150.28 | 80.85 | |
| Working Capital Days | 298.64 | 12.59 | 127.75 | 200.39 | 561.54 | 133.34 | 89.20 | 149.23 | 210.14 | 164.47 | 89.84 | |
| ROCE % | 1.84% | 3.43% | 6.85% | 5.65% | 2.23% | 3.48% | 9.15% | 5.88% | 3.70% | 2.84% | 3.84% | 7.65% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Dec 2025 | |
|---|---|---|---|---|---|
| Number of Permanent Employees Number |
|
||||
| Manufacturing Facility Area (Badlapur) Square Meters |
|||||
| Logistics Fleet Size (TEU Containers) Units |
|||||
| SSM Formulations - Annual Capsule Capacity Crore Capsules |
|||||
| SSM Formulations - Annual Tablet Capacity Crore Tablets |
|||||
| SSM Formulations - Capsule Capacity Utilization Percentage |
|||||
| SSM Formulations - Product Manufacturing Permissions Number |
|||||
| SSM Formulations - Tablet Capacity Utilization Percentage |
|||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 May - Newspaper publication dated 27th May, 2026 for Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter and Year ended 31st March, 2026 …
-
Announcement under Regulation 30 (LODR)-Change in Management
26 May - M/s NP Rajput & Co appointed internal auditor for FY 2026-27 on 26 May 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting
26 May - Board approved audited FY26 results; standalone profit Rs358.11 lakh, consolidated profit Rs532.47 lakh; appointed internal auditor for FY27.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
25 May - Filed annual secretarial compliance report for FY2026; SEBI levied Rs.1 lakh penalty on promoter entity.
-
Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ending On 31St March, 2026, In Accordance With Regulation 33 Of The SEBI Listing Regulation.
21 May - Board meeting on 26 May 2026 to approve audited FY2026 standalone and consolidated results; trading window closed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.